Blood donors are deferred from donating blood for several reasons, either permanently or temporarily. Losses related to disease marker rates are well established. Donor and donation losses for other reasons, however, have not been extensively quantified. This study quantified the rate of and reasons for donor deferral among Delhi donors. A retrospective study was conducted by reviewing the deferral donor records from 1 January 2007 to 31 December 2008. The percentage of deferred donors was 9% with majority of them (91.0%) being deferred for temporary reasons. Anemia was the most frequent cause for donor rejection (32.8%). Permanent deferral accounted for 9.1% with hypertension being the most common cause (29.4%) in this category.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Pre-screening donor eligibility to avoid a deferral in the blood donation center: A retrospective cohort study.
Transfusion
January 2025
Research and Development, Australian Red Cross Lifeblood, Melbourne, Victoria, Australia.
Background: The application of a temporary deferral when attempting to donate has a negative impact on retention. Little has been done to reduce the likelihood of a donor attending to donate, only to be found to be ineligible. The aim of this study was to determine the effectiveness of pre-screening donors when making an appointment, to prevent in-center deferrals.
View Article and Find Full Text PDF[Less iron deficiency in whole-blood donors: the effect of ferritin-guided donation intervals].
Ned Tijdschr Geneeskd
December 2024
Sanquin Research, afd. Donor Health, Amsterdam.
Objective: To evaluate the effect of ferritin-guided donation intervals on haemoglobin (Hb) and ferritin levels, iron deficiency and low Hb deferrals in whole-blood donors.
Design: A cluster-randomized stepped-wedge trial.
Methods: In 2017-2019, Sanquin gradually implemented ferritin-guided donation intervals.
Bridging the critical gap between infectious disease blood donation screening and connection to healthcare services: the American Chagas disease example.
J Public Health Policy
December 2024
Institute for Infectious Disease Translational Research, University of South Carolina, Columbia, SC, USA.
Chagas disease (Trypanosoma cruzi infection) affects ~ 290,000 USA residents and is included in routine blood donation screening panels. Donors are notified of positive T. cruzi-screening results, deferred from donation, and given limited information for next steps.
View Article and Find Full Text PDFViability of Plasmodium falciparum parasites in human plasma under different storage conditions.
Vox Sang
December 2024
Office of Blood Research and Review, Center for Biologics Evaluation and Review, Food and Drug Administration, Silver Spring, Maryland, USA.
Background And Objectives: Malaria risk deferral policies are important for mitigating the risk of transfusion-transmitted malaria and apply to all transfusable components, including plasma. While donors of plasma components are deferred for malaria risk in the United States, the viability of intraerythrocytic Plasmodium falciparum parasites present in human plasma components stored under different temperatures and durations has not been previously reported.
Materials And Methods: We spiked human plasma with a low level of ring-stage P.
JAK2-V617F mutation among blood donors: A meta-analysis.
Saudi Med J
December 2024
From the Department of Preventive Medicine (Alsharif, Alharazi), Directorate of Health Affairs; from the Hematology Department (Mansory, Badawi), Faculty of Medicine, King Abdulaziz University; and from the Hematology Research Unit (Mansory, Badawi), King Fahd Medical Research Center, King Abdulaziz University, and from the Blood Transfusion Services Unit (Badawi), King Abdulaziz University Hospital, Jeddah, Kingdom of Saudi Arabia.
Objectives: To systematically review evidence on the prevalence of the JAK2V617F (JAK2) mutation and polycythemia vera (PV) among all blood donors, focusing on those with elevated hematocrit. Although blood donors are generally healthy, considering a preclinical stage of myeloproliferative neoplasm, especially in those with polycythemia, is crucial. Evidence on managing these donors is limited.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!